Carvedilol efficiently protects kidneys without affecting the antitumor efficacy of cisplatin in mice

Chemico-Biological Interactions

Volumn 206, Issue 1, 2013, Pages 90-99

  Carvalho Rodrigues, Maria A ^a   Da Silva Faria, Marcia C ^a   Dos Santos, Neife A G ^a   Gobe, Glenda C ^b   Dos Santos, Antonio Cardozo ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b PRINCESS ALEXANDRA HOSPITAL   (Australia)

Author keywords

Carvedilol; Cisplatin; Kidneys; Nephrotoxicity; Sarcoma 180

Indexed keywords

CARVEDILOL; CASPASE 3; CISPLATIN; CREATININE; PROTEIN BAX;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER SURVIVAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG COMPETITION; DRUG EFFICACY; DRUG MECHANISM; ENZYME ACTIVITY; KIDNEY INJURY; MALE; MOUSE; NONHUMAN; OXIDATIVE STRESS; PROTEIN EXPRESSION; RENAL PROTECTION; SARCOMA; TUMOR REGRESSION; TUMOR VOLUME; UREA NITROGEN BLOOD LEVEL;

CARVEDILOL; CISPLATIN; KIDNEYS; NEPHROTOXICITY; SARCOMA-180;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CARBAZOLES; CISPLATIN; DOSE-RESPONSE RELATIONSHIP, DRUG; KIDNEY; MALE; MICE; MOLECULAR STRUCTURE; NEOPLASMS, EXPERIMENTAL; OXIDATIVE STRESS; PROPANOLAMINES; STRUCTURE-ACTIVITY RELATIONSHIP; XENOGRAFT MODEL ANTITUMOR ASSAYS;

MUS; RATTUS;

EID: 84885955806     PISSN: 00092797     EISSN: 18727786     Source Type: Journal    
DOI: 10.1016/j.cbi.2013.08.015     Document Type: Article

References (75)

1. D. Lebwohl, and R. Canetta Clinical development of platinum complexes in cancer therapy: an historical perspective and an update Eur. J. Cancer 34 1998 1522 1534 (Pubitemid 28446332)
2. P.M. Price, F. Yu, P. Kaldis, E. Aleem, G. Nowak, R.L. Safirstein, and J. Megyesi Dependence of cisplatin-induced cell death in vitro and in vivo on cyclin-dependent kinase 2 J. Am. Soc. Nephrol. 17 2006 2434 2442 (Pubitemid 44300959)
3. X. Han, J. Yue, and R.W. Chesney Functional TauT protects against acute kidney injury J. Am. Soc. Nephrol. 20 2009 1323 1332
4. E. Cvitkovic Cumulative toxicities from cisplatin therapy and current cytoprotective measures Cancer Treat. Rev. 24 1998 265 281 (Pubitemid 28488281)
5. S. Diwanay, M. Gautam, and B. Patwardhan Cytoprotection and immunomodulation in cancer therapy Curr. Med. Chem. Anticancer Agents 4 2004 479 490 (Pubitemid 39406261)
6. J.L. Koyner, R. Sher Ali, and P.T. Murray Antioxidants. Do they have a place in the prevention or therapy of acute kidney injury? Nephron Exp. Nephrol. 109 2008 e109 e117
7. N.A. Dos Santos, M.A. Carvalho Rodrigues, N.M. Martins, and A.C. Dos Santos Cisplatin-induced nephrotoxicity and targets of nephroprotection: an update Arch. Toxicol. 86 2012 1233 1250
8. M.A. Rodrigues, J.L. Rodrigues, N.M. Martins, F. Barbosa, C. Curti, N.A. Santos, and A.C. Santos Carvedilol protects against the renal mitochondrial toxicity induced by cisplatin in rats Mitochondrion 10 2010 46 53
9. M.A. Rodrigues, J.L. Rodrigues, N.M. Martins, F. Barbosa, C. Curti, N.A. Santos, and A.C. Santos Carvedilol protects against cisplatin-induced oxidative stress, redox state unbalance and apoptosis in rat kidney mitochondria Chem. Biol. Interact. 189 2011 45 51
10. R.R. Ruffolo, and G.Z. Feuerstein Carvedilol case history: the discovery and development of the first beta-blocker for the treatment of congestive heart failure Expert Opin. Drug Discov. 1 2006 85 89
11. N. Noguchi, K. Nishino, and E. Niki Antioxidant action of the antihypertensive drug, carvedilol, against lipid peroxidation Biochem. Pharmacol. 59 2000 1069 1076 (Pubitemid 30110499)
12. T.L. Yue, H.Y. Cheng, P.G. Lysko, P.J. McKenna, R. Feuerstein, J.L. Gu, K.A. Lysko, L.L. Davis, and G. Feuerstein Carvedilol, a new vasodilator and beta adrenoceptor antagonist, is an antioxidant and free radical scavenger J. Pharmacol. Exp. Ther. 263 1992 92 98
13. K.V. Kumar, A.A. Shifow, M.U. Naidu, and K.S. Ratnakar Carvedilol: a beta blocker with antioxidant property protects against gentamicin-induced nephrotoxicity in rats Life Sci. 66 2000 2603 2611 (Pubitemid 30327475)
14. P.J. Oliveira, J.A. Bjork, M.S. Santos, R.L. Leino, M.K. Froberg, A.J. Moreno, and K.B. Wallace Carvedilol-mediated antioxidant protection against doxorubicin-induced cardiac mitochondrial toxicity Toxicol. Appl. Pharmacol. 200 2004 159 168 (Pubitemid 39346022)
15. P. Spallarossa, S. Garibaldi, P. Altieri, P. Fabbi, V. Manca, S. Nasti, P. Rossettin, G. Ghigliotti, A. Ballestrero, F. Patrone, A. Barsotti, and C. Brunelli Carvedilol prevents doxorubicin-induced free radical release and apoptosis in cardiomyocytes in vitro J. Mol. Cell. Cardiol. 37 2004 837 846 (Pubitemid 39222076)
16. B. Rosenberg, L. VanCamp, J.E. Trosko, and V.H. Mansour Platinum compounds: a new class of potent antitumour agents Nature 222 1969 385 386
17. K. Sugiura, and C.C. Stock Studies in a tumor spectrum. I. Comparison of the action of methylbis (2-chloroethyl)amine and 3-bis(2-chloroethyl) aminomethyl-4-methoxymethyl -5-hydroxy-6-methylpyridine on the growth of a variety of mouse and rat tumors Cancer 5 1952 382 402
18. J.B. Field Tests of compounds against sarcoma 180 in a screening project in mice Cancer Res. Suppl. 2 1955 3 52
19. W. Xiaohuai, T.J. Lewis, and D. Mitchell The tumoricidal effect of sonodynamic therapy (SDT) on S-180 sarcoma in mice Integr. Cancer Ther. 7 2008 96 102 (Pubitemid 351806540)
20. N. Pabla, G. Dong, M. Jiang, S. Huang, M.V. Kumar, R.O. Messing, and Z. Dong Inhibition of PKCdelta reduces cisplatin-induced nephrotoxicity without blocking chemotherapeutic efficacy in mouse models of cancer J. Clin. Invest. 121 2011 2709 2722
21. M.L. Gonzaga, D.P. Bezerra, A.P. Alves, N.M. de Alencar, O. Mesquita Rde, M.W. Lima, A. Soares Sde, C. Pessoa, M.O. de Moraes, and L.V. Costa-Lotufo In vivo growth-inhibition of Sarcoma 180 by an alpha-(1→4)-glucan-beta- (1→6)-glucan-protein complex polysaccharide obtained from Agaricus blazei Murill Nat. Med. (Tokyo) 63 2009 32 40
22. G. Gobe Identification of apoptosis in kidney tissue sections Methods Mol. Biol. 466 2009 175 192
23. K. Cain, and D.N. Skilleter Preparation and use of mitochondria in toxicological research K. Snell, B. Mollock, Biochemical Toxicology. A practical approach 1987 IRL Press Oxford 217 254
24. 2+ ions. A proposed model for phosphate-stimulated lipid peroxidation J. Biol. Chem. 271 1996 2929 2934
25. P.J. Hissin, and R. Hilf A fluorometric method for determination of oxidized and reduced glutathione in tissues Anal. Biochem. 74 1976 214 226
26. N. Pabla, and Z. Dong Cisplatin nephrotoxicity: mechanisms and renoprotective strategies Kidney Int. 73 2008 994 1007 (Pubitemid 351543900)
27. X. Yao, K. Panichpisal, N. Kurtzman, and K. Nugent Cisplatin nephrotoxicity: a review Am. J. Med. Sci. 334 2007 115 124 (Pubitemid 47262919)
28. N.A. Santos, C.S. Catao, N.M. Martins, C. Curti, M.L. Bianchi, and A.C. Santos Cisplatin-induced nephrotoxicity is associated with oxidative stress, redox state unbalance, impairment of energetic metabolism and apoptosis in rat kidney mitochondria Arch. Toxicol. 81 2007 495 504 (Pubitemid 47012464)
29. K.J. Cullen, Z. Yang, L. Schumaker, and Z. Guo Mitochondria as a critical target of the chemotherapeutic agent cisplatin in head and neck cancer J. Bioenerg. Biomembr. 39 2007 43 50 (Pubitemid 46877172)
30. A. Korkmaz, and D. Kolankaya The protective effects of ascorbic acid against renal ischemia-reperfusion injury in male rats Ren. Fail. 31 2009 36 43
31. J.G. Zhang, and W.E. Lindup Cisplatin nephrotoxicity: decreases in mitochondrial protein sulphydryl concentration and calcium uptake by mitochondria from rat renal cortical slices Biochem. Pharmacol. 47 1994 1127 1135
32. H.A. El-Beshbishy, S.A. Bahashwan, H.A. Aly, and H.A. Fakher Abrogation of cisplatin-induced nephrotoxicity in mice by alpha lipoic acid through ameliorating oxidative stress and enhancing gene expression of antioxidant enzymes Eur. J. Pharmacol. 668 2011 278 284
33. A.A. Fouad, A.I. Al-Sultan, S.M. Refaie, and M.T. Yacoubi Coenzyme Q10 treatment ameliorates acute cisplatin nephrotoxicity in mice Toxicology 274 2010 49 56
34. P. Mukhopadhyay, B. Horvath, Z. Zsengeller, J. Zielonka, G. Tanchian, E. Holovac, M. Kechrid, V. Patel, I.E. Stillman, S.M. Parikh, J. Joseph, B. Kalyanaraman, and P. Pacher Mitochondrial-targeted antioxidants represent a promising approach for prevention of cisplatin-induced nephropathy Free Radic. Biol. Med. 52 2012 497 506
35. D.C. Dobyan, J. Levi, C. Jacobs, J. Kosek, and M.W. Weiner Mechanism of cis-platinum nephrotoxicity: II. Morphologic observations J. Pharmacol. Exp. Ther. 213 1980 551 556 (Pubitemid 10085160)
36. H. Tanaka, E. Ishikawa, S. Teshima, and E. Shimizu Histopathological study of human cisplatin nephropathy Toxicol. Pathol. 14 1986 247 257 (Pubitemid 16016992)
37. P.E. Kintzel Anticancer drug-induced kidney disorders Drug Saf. 24 2001 19 38
38. G. Singh A possible cellular mechanism of cisplatin-induced nephrotoxicity Toxicology 58 1989 71 80 (Pubitemid 19233700)
39. K. Sueishi, K. Mishima, K. Makino, Y. Itoh, K. Tsuruya, H. Hirakata, and R. Oishi Protection by a radical scavenger edaravone against cisplatin-induced nephrotoxicity in rats Eur. J. Pharmacol. 451 2002 203 208 (Pubitemid 35253961)
40. P.D. Sanchez-Gonzalez, F.J. Lopez-Hernandez, F. Perez-Barriocanal, A.I. Morales, and J.M. Lopez-Novoa Quercetin reduces cisplatin nephrotoxicity in rats without compromising its anti-tumour activity Nephrol. Dial. Transplant. 26 2011 3484 3495
41. E.V. Schmalhausen, E.B. Zhlobek, I.N. Shalova, O. Firuzi, L. Saso, and V.I. Muronetz Antioxidant and prooxidant effects of quercetin on glyceraldehyde-3-phosphate dehydrogenase Food Chem. Toxicol. 45 2007 1988 1993 (Pubitemid 47238214)
42. M.J. Laughton, B. Halliwell, P.J. Evans, and J.R. Hoult Antioxidant and pro-oxidant actions of the plant phenolics quercetin, gossypol and myricetin. Effects on lipid peroxidation, hydroxyl radical generation and bleomycin-dependent damage to DNA Biochem. Pharmacol. 38 1989 2859 2865 (Pubitemid 19219848)
43. R. Kachadourian, H.M. Leitner, and B.J. Day Selected flavonoids potentiate the toxicity of cisplatin in human lung adenocarcinoma cells: a role for glutathione depletion Int. J. Oncol. 31 2007 161 168
44. H.J. Cross, M. Tilby, J.K. Chipman, D.R. Ferry, and A. Gescher Effect of quercetin on the genotoxic potential of cisplatin Int. J. Cancer 66 1996 404 408 (Pubitemid 26163612)
45. N.A.G. Santos, A.C. Santos, Antioxidants and inhibition of cisplatin-induced kidney injury: role of mitochondria, in: Kenneth J. Dornfeld, Douglas R. Spitz, Koyamangalath Krishnan, David Guis (Eds.), Oxidative Stress in, Cancer Biology and Therapy, Humana Press Inc. 2012, pp. 407-425.
46. D.L. Santos, A.J. Moreno, R.L. Leino, M.K. Froberg, and K.B. Wallace Carvedilol protects against doxorubicin-induced mitochondrial cardiomyopathy Toxicol. Appl. Pharmacol. 185 2002 218 227 (Pubitemid 36062795)
47. D. Jovanovic, D. Jovovic, N. Mihailovic-Stanojevic, Z. Miloradovic, J. Dimitrijevic, N. Maksic, and L. Djukanovic Influence of carvedilol on chronic renal failure progression in spontaneously hypertensive rats with adriamycin nephropathy Clin. Nephrol. 63 2005 446 453 (Pubitemid 40872623)
48. W. Arozal, K. Watanabe, P.T. Veeraveedu, M. Ma, R.A. Thandavarayan, V. Sukumaran, K. Suzuki, M. Kodama, and Y. Aizawa Protective effect of carvedilol on daunorubicin-induced cardiotoxicity and nephrotoxicity in rats Toxicology 274 2010 18 26
49. J. Goodman, and P. Hochstein Generation of free radicals and lipid peroxidation by redox cycling of adriamycin and daunomycin Biochem. Biophys. Res. Commun. 77 1977 797 803 (Pubitemid 8154954)
50. D. Wang, and S.J. Lippard Cellular processing of platinum anticancer drugs Nat. Rev. Drug. Discov. 4 2005 307 320 (Pubitemid 41130944)
51. W. Lieberthal, S.A. Menza, and J.S. Levine Graded ATP depletion can cause necrosis or apoptosis of cultured mouse proximal tubular cells Am. J. Physiol. 274 1998 F315 F327
52. N. Ueda, G.P. Kaushal, and S.V. Shah Apoptotic mechanisms in acute renal failure Am. J. Med. 108 2000 403 415 (Pubitemid 30162959)
53. M.H. Hanigan, and P. Devarajan Cisplatin nephrotoxicity: molecular mechanisms Cancer Ther. 1 2003 47 61
54. R. Khan, A.Q. Khan, W. Qamar, A. Lateef, M. Tahir, M.U. Rehman, F. Ali, and S. Sultana Chrysin protects against cisplatin-induced colon. toxicity via amelioration of oxidative stress and apoptosis: probable role of p38MAPK and p53 Toxicol. Appl. Pharmacol. 258 2012 315 329
55. S. Silici, O. Ekmekcioglu, M. Kanbur, and K. Deniz The protective effect of royal jelly against cisplatin-induced renal oxidative stress in rats World J. Urol. 29 2011 127 132
56. M.O. Dillioglugil, H. Maral Kir, M.D. Gulkac, A. Ozon Kanli, H.K. Ozdogan, O. Acar, and O. Dillioglugil Protective effects of increasing vitamin E and a doses on cisplatin-induced oxidative damage to kidney tissue in rats Urol. Int. 75 2005 340 344 (Pubitemid 41752584)
57. M. Loeffler, and G. Kroemer The mitochondrion in cell death control: certainties and incognita Exp. Cell Res. 256 2000 19 26 (Pubitemid 30211162)
58. N.A.G. Santos, C.S. Catao, N.M. Martins, C. Curti, M.L.P. Bianchi, and A.C. Santos Cisplatin-induced nephrotoxicity is associated with oxidative stress, redox state unbalance, impairment of energetic metabolism and apoptosis in rat kidney mitochondria Arch. Toxicol. 81 2007 495 504 (Pubitemid 47012464)
59. Eastman A. The mechanism of action of cisplatin: from adducts to apoptosis B. Lippert, Cisplatin: Chemistry and Biochemistry of a Leading Anticancer Drug 1999 Wiley-VCH New York 111 135
60. R.D. Wainford, R.J. Weaver, K.N. Stewart, P. Brown, and G.M. Hawksworth Cisplatin nephrotoxicity is mediated by gamma glutamyltranspeptidase, not via a C-S lyase governed biotransformation pathway Toxicology 249 2008 184 193
61. T.L. Yue, P.G. Lysko, F.C. Barone, J.L. Gu, R.R. Ruffolo Jr., and G.Z. Feuerstein Carvedilol, a new antihypertensive drug with unique antioxidant activity: potential role in cerebroprotection Ann. N. Y. Acad. Sci. 738 1994 230 242
62. T.L. Yue, P.J. McKenna, P.G. Lysko, J.L. Gu, K.A. Lysko, R.R. Ruffolo Jr., and G.Z. Feuerstein SB 211475, a metabolite of carvedilol, a novel antihypertensive agent, is a potent antioxidant Eur. J. Pharmacol. 251 1994 237 243 (Pubitemid 24061099)
63. R.R. Ruffolo, and G.Z. Feuerstein Carvedilol case history: the discovery and development of the first β-blocker for the treatment of congestive heart failure Expert Opin. Drug Discov. 1 2006 85 89
64. P. Dandona, H. Ghanim, and D.P. Brooks Antioxidant activity of carvedilol in cardiovascular disease J. Hypertens. 25 2007 731 741 (Pubitemid 46398866)
65. N.A. dos Santos, N.M. Martins, C. Curti, L. Pires Bianchi Mde, and A.C. dos Santos Dimethylthiourea protects against mitochondrial oxidative damage induced by cisplatin in liver of rats Chem. Biol. Interact. 170 2007 177 186 (Pubitemid 350088746)
66. N.A. Santos, C.S. Bezerra, N.M. Martins, C. Curti, M.L. Bianchi, and A.C. Santos Hydroxyl radical scavenger ameliorates cisplatin-induced nephrotoxicity by preventing oxidative stress, redox state unbalance, impairment of energetic metabolism and apoptosis in rat kidney mitochondria Cancer Chemother. Pharmacol. 61 2008 145 155 (Pubitemid 47512636)
67. R.H. Lee, J.M. Song, M.Y. Park, S.K. Kang, Y.K. Kim, and J.S. Jung Cisplatin-induced apoptosis by translocation of endogenous Bax in mouse collecting duct cells Biochem. Pharmacol. 62 2001 1013 1023
68. M.S. Park, M. De Leon, and P. Devarajan Cisplatin induces apoptosis in LLC-PK1 cells via activation of mitochondrial pathways J. Am. Soc. Nephrol. 13 2002 858 865 (Pubitemid 34274081)
69. M. Jiang, N. Pabla, R.F. Murphy, T. Yang, X.M. Yin, K. Degenhardt, E. White, and Z. Dong Nutlin-3 protects kidney cells during cisplatin therapy by suppressing Bax/Bak activation J. Biol. Chem. 282 2007 2636 2645 (Pubitemid 47076791)
70. Q. Wei, G. Dong, J. Franklin, and Z. Dong The pathological role of Bax in cisplatin nephrotoxicity Kidney Int. 72 2007 53 62 (Pubitemid 47014446)
71. J.M. Adams, and S. Cory Life-or-death decisions by the Bcl-2 protein family Trends Biochem. Sci. 26 2001 61 66 (Pubitemid 32124712)
72. E. Daugas, S.A. Susin, N. Zamzami, K.F. Ferri, T. Irinopoulou, N. Larochette, M.C. Prevost, B. Leber, D. Andrews, J. Penninger, and G. Kroemer Mitochondrio-nuclear translocation of AIF in apoptosis and necrosis FASEB J. 14 2000 729 739 (Pubitemid 30198571)
73. M. Jiang, Q. Wei, J. Wang, Q. Du, J. Yu, L. Zhang, and Z. Dong Regulation of PUMA-alpha by p53 in cisplatin-induced renal cell apoptosis Oncogene 25 2006 4056 4066 (Pubitemid 44024868)
74. D.H. Kim, Y.J. Jung, J.E. Lee, A.S. Lee, K.P. Kang, S. Lee, S.K. Park, M.K. Han, S.Y. Lee, K.M. Ramkumar, M.J. Sung, and W. Kim SIRT1 activation by resveratrol ameliorates cisplatin-induced renal injury through deacetylation of p53 Am. J. Physiol. Ren. Physiol. 301 2011 F427 F435
75. S.M. Bonsib, Renal anatomy and histology, in: J.C.O. Jennette, L. Jean, Schwartz, M. Melvin, Silva, G. Fred (Eds.) Hepinstall's Pathology of the Kidney, Lippincott Williams & Wilkins 2007, pp. 13-14.